How we score →

Keeps Review

✓ Updated July 2026 By the TelehealthIndex Editorial Team · How we score Fair · #4 in Hair Loss & Dermatology
Advertising Disclosure: TelehealthIndex is reader-supported. If you sign up with a provider through links on this page, we may earn a commission at no extra cost to you. Commissions never influence our scores or rankings — several of our top-rated providers pay us nothing. How we score → · Full disclosure →

Keeps score

Fair · #4 in Hair Loss & Dermatology · Data as of July 2026
Clinical credibilityWeak
Regulatory & safety recordMinor deductions
Transparency & trustWeak
Access & coverageMixed
Customer experienceGood
Value & pricingExceptional
Pillar ratings are qualitative summaries of our internal rubric; we do not publish the point weights. Read the full methodology →

TelehealthIndex scores and rankings are editorial opinions resulting from our selection, weighting, and interpretation of the factors described in our methodology.

What it is

Men's hair-loss pure play: finasteride/minoxidil from $10/mo; dermatologist medical advisors; BBB A+ since 2018.

Strengths

  • Available nationwide (50 states)
  • Money-back guarantee
  • Lower-cost pricing for the category

Considerations

  • Parent sale to GLP-1 marketer Remedy Meds (announced Sept 2025) - integration risk
  • Upsell drift toward pricier compounded products; compounded topical finasteride under FDA Apr 2025 adverse-event alert (category-wide)
Note: this provider offers compounded medications for one or more services. Compounded medications are not FDA-approved.
Founded2018
OwnershipThirty Madison (Remedy Meds acquisition pending)
AvailabilityNationwide (50 states)
InsuranceNo
Money-back guaranteeYes
PricingFinasteride ~$25/mo; minoxidil ~$11-17/mo; compounded lines from $30/mo; quarterly billing
Visit Keeps We may earn a commission — disclosure.

Alternatives to consider

Curology Good · #3 in Hair Loss & Dermatology — read review → Happy Head Fair · #5 in Hair Loss & Dermatology — read review →

Data as of July 19, 2026. Scores are editorial opinions reflecting documented business practices, transparency, pricing, access, and nonclinical consumer-service factors — not clinical quality or outcomes. Found an error? Report it →